Speakers

She holds a PhD in Biochemistry from the University Paris Diderot (France). As a postdoctoral fellow, she joined Pr. Roy Mariuzza’s lab at the Center for Advanced Research in Biotechnology, University of Maryland (USA), where she studied Natural Killer cell receptors, and later joined Dr. R. Jockers’ team at the Institut Cochin in Paris to study membrane receptor function. She is now an INSERM research director and co-leads the "Functional Pharmacology and Pathophysiology of Membrane Receptors" team at the Institut Cochin. Her research combines molecular, cellular and in vivo approaches to study how membrane receptors regulate cell function and their role in obesity and type 2 diabetes, focusing on leptin receptor and GPCRs.

Julien Hanson graduated in Pharmacy at the University of Liège in 2002. He performed a PhD in Medicinal Chemistry at the same University, in the laboratory of Medicinal Chemistry, under the guidance of Jean-Michel Dogné and Bernard Pirotte. In 2007 he joined the Stefan Offermanns lab at the Pharmacology Institute of the University of Heidelberg in Germany for post-doctoral studies. He is now a Senior Research associate of the FRS-FNRS and Principal Investigator of the laboratory of Molecular Pharmacology at the GIGA and CIRM research centers of the University of Liège. His lab investigates the function and signaling of understudied G Protein-Coupled Receptors, principally orphans.

PhD degree in Pharmacology (University of Paris V, France), followed by post-doctoral training in the laboratory of Prof. Thue W. Schwartz (Denmark) and of Dr. Ralf Jockers (Paris, France). Since 2013, she is a permanent researcher at the French National Institute for Medical Research (INSERM) in the laboratory of Dr Ralf Jockers at the Institut Cochin (Paris, France). Her work focus on the melatonin receptor heteromers as potential therapeutic targets, as well as on the development of pharmacological tools to decipher the action mode of ligands and improve ligand selectivity.

Professor at USP's Department of Clinical and Toxicological Analyses, former ASCB International Affairs Committee President (2020-2022), and Fellow of ASCB and TWAS. Her lab identified four GPCR candidates in Plasmodium, including PfSR25, a potassium sensor triggering Ca²⁺ signaling. Knock-out studies revealed PfSR25-deficient parasites are less resistant to antimalarials, highlighting its potential as a target for new therapies. The primary focus of her research activity is to elucidate how malaria parasites signal in the various stages of their life cycle in efforts to explore new venues for clinical intervention. Her team combines work on live cell microscopy with state-of-the-art molecular techniques. Her laboratory engages in the screening of synthetic and natural compounds aiming to discover new anti-malarial drugs.

Graduated in Pharmacy and Biochemistry (2002), MS (2005), and Ph.D. (2007) in Pharmacology from the University of Sao Paulo, Brazil. Research fellow in the Institute of Infection, Immunity, and Inflammation at the University of Glasgow UK (2008-2011). Currently at Ribeirao Preto Medical School – University of Sao Paulo as a Full Professor in Immunopharmacology, Principal investigator in the Center for Research in Inflammatory Diseases (CRID), and Director of the International Research Laboratory ImunoHealth from CNRS. The research developed by Jose Alves-Filho’s laboratory aims at understanding the cellular and molecular mechanisms regulating differentiation and plasticity of effector and regulatory immune cells and how these can be targeted therapeutically to overcome the pathologic outcome of immune-mediated inflammatory diseases. 

Full Professor at the Faculty of Pharmaceutical Sciences of the University of São Paulo; Level 1A Productivity Fellow of CNPq and Full Member of the Brazilian Academy of Sciences. Coordinates regular and thematic projects funded by FAPESP. Has supervised 23 Master's students, 14 Ph.D. students, and 8 postdoctoral researchers. Investigates the mechanisms of innate inflammation control and the mechanisms of immunotoxicity caused by environmental pollutants. Has published 144 papers in international journals, with 3,668 citations and an h-index of 36 (Web of Science) and 43 (Google Scholar).

Professor of the Department of Genetics and Evolutionary Biology of the University of Sao Paulo - Brazil. 15 years of experience in biomedical and biotechnology research. Co-founder of several biotech startups. Scientific advisor for biotech startups. Inventor of several patents in advanced therapies (e.g. oncolytic viral therapy, stem cell-based products, etc), author of several high-impact papers in the field (e.g. Nature, Biofabrication, Cancer Research, etc), and an active member of International Society for Stem Cell Research (ISSCR) and International Society of Cell and Gene Therapy. Currently working in Business Development, connecting the private sector to Academia, and developing partnerships in stem cell-based therapy, bioengineering, gene editing, CAR-T technology, xenotransplantation, cell and gene therapy, and regenerative medicine.

Source: The Goulart Lab website

Adriano D. Andricopulo earned his BSc in Chemistry (1993) from the Federal University of Santa Maria, Brazil, followed by a MSc in Organic Chemistry (1996) from the Federal University of Santa Catarina. He obtained his PhD in Medicinal Chemistry (1999) from the Federal University of Santa Catarina and the University of Michigan, USA. From 1999 to 2002, he conducted postdoctoral research in Medicinal Chemistry at the University of Michigan. He is currently a Full Professor of Medicinal Chemistry at the University of São Paulo (USP), Brazil, with expertise in medicinal chemistry and drug discovery, particularly in neglected tropical diseases, cancer, and the application of artificial intelligence and chemical databases in natural products research.

Veterinary by the Federal University of Bahia (UFBA), Master in Biotechnology from the State University of Feira de Santana (UEFS), PhD from the University of São Paulo and Mednarodna podiplomska šola Jožefa Stefana (2019). Founded of Biolinker, a synthetic biology company working on new ways of expressing and purifying proteins — and providing solutions on top of that. We are working with Covid-19, antimicrobial peptides as biopreservatives, kits for cell-free protein synthesis and protein on-demand.

Source: LinkedIn 

Professor of hematology at USP's Ribeirão Preto Medical School and coordinator of biotechnology and the Advanced Therapies Center (NUTERA) at the Ribeirão Preto Blood Center. He is a member of the Medullary Failure Committee and the Non-Hodgkin's Lymphoma Committee of the ABHH, and of the Brazilian Medullary Failure Group. He is the Principal Investigator of the phase I/II “CARTHEDRALL” multicenter study evaluating the use of anti-CD19 CAR-T cells produced at the Ribeirão Preto Blood Center for the treatment of acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). Responsible for conducting cell therapy studies aimed at expanding the application of CAR-T cells to other diseases and the development of other modalities, such as CAR-NK cells. 

Full professor of FD-USP. Administrative director of FAPESP.

Graduated in Biomedicine from the Federal University of Pará (1983), Master in Biological Sciences (Microbiology) from the Federal University of Minas Gerais (1991) and PhD in Microbiology and Immunology from the Federal University of São Paulo (1998). She did post-doctoral work at the Federal University of São Paulo from 1999-2001. She is currently Full Professor and Head of the Department of Clinical and Toxicological Analysis at the Faculty of Pharmaceutical Sciences of the University of São Paulo (FCF-USP). She chairs the Faculty's Institutional Academic Planning Committee. She works in the area of Parasite Protozoology, specifically in human malaria. Her current projects are focused on pre-clinical tests for vaccination against malaria caused by Plasmodium vivax. She is a member of the National Institute of Vaccine Science and Technology (INCTV) and the Vaccine Research Support Center (NAP, PRP-USP).

Source: FCF USP